At MD Anderson, we work in partnership with our patients to enable groundbreaking research to better prevent, diagnose and treat cancer. Grounded in a culture of collaboration, connectivity, and data-based science, our work yields transformative findings that are shifting patient care and improving patients¡¯ lives across the globe.
At the American Society for Radiation Oncology (ASTRO) Annual Meeting, our experts will showcase their pacesetting research and join colleagues for discussion on the latest advances in radiation oncology.
See highlights from our presentations, details about onsite networking opportunities with our experts and information on our open positions for faculty and trainees below.
Featured News
Using math to answer cancer¡¯s biggest questions
One of the most important parts of science is asking the right questions. As an engineer trying to break into medical research, , found that some of the questions he was trying to answer weren¡¯t actually all that important to oncologists in the clinic and they weren¡¯t translating into new or better treatments for patients.
But Butner was certain that if the right mathematical methods that have traditionally been used to solve engineering and physics problems were applied to medicine, then he could tap into opportunities and advancements in therapeutic approaches that could change patients¡¯ lives.
He felt compelled to keep chasing the biggest problems in cancer treatment. He knew if he was going to get anywhere, he needed to team up with clinicians who had a better understanding of diseases, treatments and the unique challenges they face in clinical practice. If they could combine their vast knowledge of cancer with his deeper understanding of mathematical models, Butner was certain they could make advancements.
Partnering with oncologists
In October 2023, Butner came to MD Anderson, where he is now an assistant professor in Radiation Oncology. He said clinicians haven¡¯t always been open to the idea of working with mathematicians. But that¡¯s starting to change, and MD Anderson is leading the way.
¡°MD Anderson is full of innovative thinkers who were not only willing but excited to think outside the box to give mathematical modeling a chance, and this forward thinking has now led to the exciting new Institute for Data Science in Oncology,¡± Butner says.
Butner has used mathematical equations to predict how effective checkpoint inhibitor therapy, a type of immunotherapy, will be in solid tumors, and how to more accurately determine surgical margins from calcification seen in mammograms in patients with ductal carcinoma in situ, a type of breast cancer.
Looking to the future
Now, he¡¯s looking to use equations to better understand the way combination therapies interact to revolutionize how individual treatment plans are designed.
¡°It¡¯s common for mathematical models to describe only one type of treatment, but in the clinic, patients often receive multiple therapies to better address their individual needs,¡± Butner says. ¡°These therapies may interact in complex ways, and if we can quantify these interactions and how they affect the patient and the disease, then we can use known optimization methods to engineer personalized treatment plans to better achieve long-term disease control.¡±
He and his team are now building combination models of immunotherapy used together with radiation, and they are already planning models of other combination therapies.
Butner hopes that the right equations will eventually change the way treatment plans are currently designed by providing oncologists with one or more optimized personalized treatment plans that can be recalculated and adapted to the unique needs and goals of each patient as their disease changes over time.
Butner often hears others ask, ¡°Math is so complicated. Can¡¯t we just use artificial intelligence (AI) instead?¡±
Butner believes that artificial intelligence, like mathematical equations, is another tool we can use to make progress on cancer treatment.
¡°In the future, we¡¯ll use both AI and computational models,¡± he says. ¡°AI excels when large amounts of data are available, but this is not always the case for new technologies or approaches, like those used in the groundbreaking clinical trials happening every day at MD Anderson. Equations offer a powerful way to fill this gap; often, they can be used reliably with data from only a single patient. It¡¯s up to us as cancer researchers to determine how we think innovatively to really go beyond the limits of each method. I think that the future involves combining AI and equations in clever ways to leverage the unique strengths of each approach to exceed what we can currently do.¡±
Meet the Experts
Visit MD Anderson at Booth 2137 to network with us, ask a question, learn about training and career opportunities and continue the conversation on key presentations with our experts.
Division Head and Chair, Radiation Oncology
Exhibit Hall Hours
Sunday, Sept. 28: 10 a.m.¨C5 p.m. PT
Monday, Sept. 29: 10 a.m.¨C5 p.m. PT
Tuesday, Sept. 30: 10 a.m.¨C5 p.m. PT
Sunday, September 28
11:30 a.m.¨C12:00 p.m. PT
Building global bridges in cancer care
Assistant Professor, Radiation Oncology
Professor, Radiation Oncology
Kamaria Lee, M.D.
Resident, Radiation Oncology
Professor, Gynecologic Oncology and Reproductive Medicine
Associate Vice President, Global Oncology
Assistant Professor, Radiation Oncology
2:30¨C3 p.m. PT
Ensuring safety at the cutting edge, Part I
Physics Section Chief of Thoracic Service, Radiation Physics
3¨C4 p.m. PT
Training at MD Anderson
Professor, Genitourinary Radiation Oncology
Program Director, Advanced Radiation Oncology Fellowship
Professor and Department Chair, Gastrointestinal Radiation Oncology
Deputy Division Head for Education, Radiation Oncology
Associate Professor, Radiation Oncology
Assistant Professor, Genitourinary Radiation Oncology
Residency Associate Program Director, Radiation Oncology
Professor, Radiation Physics
Deputy Director, Medical Physics Graduate Program
Associate Professor, Radiation Oncology
Division Head and Chair, Radiation Oncology
Assistant Professor, Radiation Physics
Assistant Professor, Radiation Oncology
Professor, Radiation Oncology
Residency Program Director, Radiation Oncology
4¨C4:30 p.m. PT
Transformative techniques in thoracic cancer care
Professor, Radiation Oncology
Professor, Radiation Oncology
Monday, September 29
10¨C10:30 a.m. PT
Radiotherapy advances in hematologic malignancies
Associate Professor, Radiation Oncology
Associate Professor, Radiation Oncology
Assistant Professor, Radiation Oncology
10¨C10:30 a.m. PT
What's new in gastrointestinal cancer care
Professor and Department Chair, Gastrointestinal Radiation Oncology
Assistant Professor, Gastrointestinal Radiation Oncology
10:30¨C11 a.m. PT
Physician-scientists at MD Anderson: Innovation to impact
Assistant Professor, Central Nervous System Radiation Oncology
10:30¨C11 a.m. PT
Lessons from leaders: Meet our clinical department chairs
Professor and Chair, Gastrointestinal Radiation Oncology
Division Head and Chair, Radiation Oncology
Professor and Chair, Thoracic Radiation Oncology
Professor and Chair, Central Nervous System Radiation Oncology
Professor and Chair, Breast Radiation Oncology
11¨C11:30 a.m. PT
The future of proton therapy
Professor, Radiation Oncology
Medical Director, Proton Therapy Center
Professor, Radiation Oncology
Professor, Radiation Oncology
11:30 a.m.¨C12:00 p.m. PT
New insights in gynecological cancers
Professor, Radiation Oncology
Professor, Radiation Oncology
12¨C12:30 p.m. PT
Innovations in head and neck cancer
Professor, Radiation Oncology
Assistant Professor, Radiation Oncology
Professor, Radiation Oncology
3¨C3:30 p.m. PT
AI reality check: Separating hope from hype
Professor, Central Nervous System Radiation Oncology
Chief Data Officer, Vice President for Data Impact and Governance
Professor, Radiation Physics and Imaging Physics
Senior Vice President and Chief Technology and Digital Officer
3¨C3:30 p.m. PT
Innovations driving outcomes in genitourinary cancers
Professor, Genitourinary Radiation Oncology
Professor, Genitourinary Radiation Oncology
Associate Professor, Genitourinary Radiation Oncology
Phuoc Tran, M.D., Ph.D.
Professor and Chair, Genitourinary Radiation Oncology
Tuesday, September 30
10¨C10:30 a.m. PT
Breakthroughs in breast cancer
Assistant Professor, Radiation Oncology
Assistant Professor, Radiation Oncology
12¨C12:30 p.m. PT
Ensuring safety at the cutting edge, Part II
Professor, Radiation Physics
Director, Radiation Dosimetry Services, Radiation Physics
Professor, Radiation Oncology
Associate Chief Patient Safety Officer, Radiation Oncology
Assistant Professor, Radiation Physics
Our research by the numbers
$1.3B
invested in research
1,556
clinical trials
188
patents awarded
From Sept. 1, 2023 to Aug. 31, 2024
Education and Training at MD Anderson
MD Anderson academic programs are competitive and comprehensive. We offer educational opportunities for learners at all levels, from programs for high school students and undergraduate degrees to graduate medical education and postdoctoral fellowships.
Why Houston?
As America's fourth-largest city, Houston has a lot to offer. Find out why Houston is a hub for scientific and medical excellence.
Institutes at MD Anderson
United by a shared mission to end cancer, MD Anderson clinicians and scientists work seamlessly together to advance groundbreaking research that can transform the field of hematology. Leveraging our unique research ecosystem, including three leading institutes, we are pioneering new prevention, diagnostic and treatment approaches to address the most pressing needs for patients with cancer.
James P. Allison Institute
The James P. Allison Institute is dedicated to advancing exceptional discovery, translational and clinical research to integrate immunobiology across disciplines and unlock the full potential of science and medicine for human health. The institute builds upon the legacy of its namesake, James P. Allison, Ph.D., who was awarded the 2018 Nobel Prize in Physiology or Medicine for his fundamental discoveries in T cell biology and his invention of ipilimumab, the first immune checkpoint inhibitor to treat cancer.
Institute for Cell Therapy Discovery & Innovation
Building upon unparalleled expertise, MD Anderson¡¯s Institute for Cell Therapy Discovery & Innovation is leading the world in developing and advancing impactful cell therapies for patients in need. By uniting the top minds in the field to lead exceptional fundamental, translational and clinical research, we're focused on creating breakthrough off-the-shelf therapies that can be readily adapted for both hematologic and solid tumors as well as devastating auto-immune conditions, infections and other diseases.
Learn more about the Institute for Cell Therapy Discovery & Innovation
Institute for Data Science in Oncology
The Institute for Data Science in Oncology (IDSO) integrates the tremendous power of meaningful data extraction and interpretation with MD Anderson¡¯s unparalleled scientific and clinical expertise to transform research and care to impact patients.